Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
This company patent portfolio is focused on the Biotechnology & Pharmaceuticals technology area. It currently has 3 pending office actions being reviewed by 3 distinct examiners. This indicates that each examiner is managing 1 pending action for the institution. The prosecution is spread across 2 distinct art units, suggesting some technical overlap among the 3 pending office actions.
MCCULLEY, MEGAN CASSANDRA is the busiest examiner with 1 pending office action. With 3 distinct examiners involved, the portfolio maintains a diversified presence at the patent office. The use of 2 distinct art units for 3 pending office actions implies that the institution's biotechnology research is concentrated within specific technical silos. Practitioners should observe that while the examiners are distinct, the art unit concentration suggests a focused area of inquiry for the pending applications across the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCULLEY, MEGAN CASSANDRA | 1 | 58.5% | +16.0% |
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
| FONTAINHAS, AURORA M | 1 | 37.9% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818481 | NEW TAU SPECIES | FONTAINHAS, AURORA M | 29d |
| 18573482 | ULTRATHIN SHELLS FOR SCULPTING LIQUIDS | MCCULLEY, MEGAN CASSANDRA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818481 | NEW TAU SPECIES | FONTAINHAS, AURORA M | 29d |
| 18573482 | ULTRATHIN SHELLS FOR SCULPTING LIQUIDS | MCCULLEY, MEGAN CASSANDRA | — |
| 18550598 | METHODS FOR THE SELECTIVE ANALYSIS OF CELLS OR ORGANELLES | KIM, YOUNG J | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573482 | ULTRATHIN SHELLS FOR SCULPTING LIQUIDS | MCCULLEY, MEGAN CASSANDRA | — | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18550598 | METHODS FOR THE SELECTIVE ANALYSIS OF CELLS OR ORGANELLES | KIM, YOUNG J | 1681 | §112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 17818481 | NEW TAU SPECIES | FONTAINHAS, AURORA M | 1675 | §103§112 | Final Rejection | 29d | Pending | Aug 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial